Akorn Inapsine

Droperidol oral formulation will be discontinued in the U.K. March 31 following concerns from the Medicines Control Agency about potential effect on cardiac QT interval associated with chronic usage. Droperidol is marketed in the U.K. by Janssen as an anti-psychotic and anti-emetic. In the U.S., droperidol is available in injectable form and marketed as a generic and by Akorn as Inapsine. Akorn said it has not observed cardiac side effects; dosing is lower and less frequent than indicated in the U.K